| Disease | Gastric cancer |
| Stage of disease/treatment | Metastatic/advanced |
| Prior therapy | 1 prior regimen |
| Type of study | Phase II, single-arm |
| Primary endpoint | Overall response rate (ORR) |
| Secondary endpoints | Progression-free survival, safety |
| Investigator’s Analysis | The present study has a very low power to detect any clinical benefit due to the limited sample size. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.